Advertisement
Review Article| Volume 37, ISSUE 1, P101-122, March 2008

Acromegaly

      Acromegaly is caused by growth hormone hypersecretion, mostly from a pituitary adenoma, driving insulin-like growth factor 1 overproduction. Manifestations include skeletal and soft tissue growth and deformities; and cardiac, respiratory, neuromuscular, endocrine, and metabolic complications. Increased morbidity and mortality require early and tight disease control. Surgery is the treatment of choice for microadenomas and well-defined intrasellar macroadenomas. Complete resection of large and invasive macroadenomas rarely is achieved; hence, their low rate of disease remission. Pharmacologic treatments, including long-acting somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, have assumed more importance in achieving biochemical and symptomatic disease control.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Endocrinology and Metabolism Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Marie P.
        On two cases of acromegaly: marked hypertrophy of the upper and lower limbs and head.
        Rev Med. 1886; 6: 297-333
        • Cushing H.
        Partial hypophysectomy for acromegaly: with remarks on the function of the hypophysis.
        Ann Surg. 1909; 50: 1002-1017
        • Evans H.
        • Long J.
        The effect of the anterior lobe of the pituitary administered intra-peritoneally upon growth, maturity and oestrus cycle of the rat.
        Anat Rev. 1921; 21: 62
        • Alexander L.
        • Appleton D.
        • Hall R.
        • et al.
        Epidemiology of acromegaly in the Newcastle region.
        Clin Endocrinol (Oxf). 1980; 12: 71-79
        • Ritchie C.M.
        • Atkinson A.B.
        • Kennedy A.L.
        • et al.
        Ascertainment and natural history of treated acromegaly in Northern Ireland.
        Ulster Med J. 1990; 59: 55-62
        • Sakharova A.A.
        • Dimaraki E.V.
        • Chandler W.F.
        • et al.
        Clinically silent somatotropinomas may be biochemically active.
        J Clin Endocrinol Metab. 2005; 90: 2117-2121
        • Chandrasekharappa S.C.
        • Guru S.C.
        • Manickam P.
        • et al.
        Positional cloning of the gene for multiple endocrine neoplasia-type 1.
        Science. 1997; 276: 404-407
        • Teh B.T.
        • Kytola S.
        • Farnebo F.
        • et al.
        Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism.
        J Clin Endocrinol Metab. 1998; 83: 2621-2626
        • Weinstein L.S.
        • Shenker A.
        • Gejman P.V.
        • et al.
        Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.
        N Engl J Med. 1991; 325: 1688-1695
        • Boikos S.A.
        • Stratakis C.A.
        Carney complex: the first 20 years.
        Curr Opin Oncol. 2007; 19: 24-29
        • Gadelha M.R.
        • Prezant T.R.
        • Une K.N.
        • et al.
        Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene.
        J Clin Endocrinol Metab. 1999; 84: 249-256
        • Vierimaa O.
        • Georgitsi M.
        • Lehtonen R.
        • et al.
        Pituitary adenoma predisposition caused by germline mutations in the AIP gene.
        Science. 2006; 312: 1228-1230
        • Daly A.F.
        • Vanbellinghen J.F.
        • Khoo S.K.
        • et al.
        Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.
        J Clin Endocrinol Metab. 2007; 92: 1891-1896
        • Thorner M.O.
        • Perryman R.L.
        • Cronin M.J.
        • et al.
        Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.
        J Clin Invest. 1982; 70: 965-977
        • Asa S.L.
        • Scheithauer B.W.
        • Bilbao J.M.
        • et al.
        A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor.
        J Clin Endocrinol Metab. 1984; 58: 796-803
        • Wilson D.M.
        • Ceda G.P.
        • Bostwick D.G.
        • et al.
        Acromegaly and Zollinger-Ellison syndrome secondary to an islet cell tumor: characterization and quantification of plasma and tumor human growth hormone-releasing factor.
        J Clin Endocrinol Metab. 1984; 59: 1002-1005
        • Ezzat S.
        • Ezrin C.
        • Yamashita S.
        • et al.
        Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor.
        Cancer. 1993; 71: 66-70
        • Melmed S.
        Acromegaly.
        N Engl J Med. 1990; 322: 966-977
        • Nelson A.E.
        • Ho K.K.
        Abuse of growth hormone by athletes.
        Nat Clin Pract Endocrinol Metab. 2007; 3: 198-199
        • Perls T.T.
        • Reisman N.R.
        • Olshansky S.J.
        Provision or distribution of growth hormone for “antiaging”: clinical and legal issues.
        JAMA. 2005; 294: 2086-2090
        • Jadresic A.
        • Banks L.M.
        • Child D.F.
        • et al.
        The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours.
        Q J Med. 1982; 51: 189-204
        • Nabarro J.D.
        Acromegaly.
        Clin Endocrinol (Oxf). 1987; 26: 481-512
        • Molitch M.E.
        Clinical manifestations of acromegaly.
        Endocrinol Metab Clin North Am. 1992; 21: 597-614
        • Lieberman S.A.
        • Bjorkengren A.G.
        • Hoffman A.R.
        Rheumatologic and skeletal changes in acromegaly.
        Endocrinol Metab Clin North Am. 1992; 21: 615-631
        • Dons R.F.
        • Rosselet P.
        • Pastakia B.
        • et al.
        Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study.
        Clin Endocrinol (Oxf). 1988; 28: 515-524
        • Scarpa R.
        • De Brasi D.
        • Pivonello R.
        • et al.
        Acromegalic axial arthropathy: a clinical case-control study.
        J Clin Endocrinol Metab. 2004; 89: 598-603
        • Ben-Shlomo A.
        • Melmed S.
        Skin manifestations in acromegaly.
        Clin Dermatol. 2006; 24: 256-259
        • Grunstein R.R.
        • Ho K.Y.
        • Berthon-Jones M.
        • et al.
        Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly.
        Am J Respir Crit Care Med. 1994; 150: 496-502
        • Garcia-Rio F.
        • Pino J.M.
        • Diez J.J.
        • et al.
        Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion.
        Am J Respir Crit Care Med. 2001; 164: 852-857
        • Donnelly P.M.
        • Grunstein R.R.
        • Peat J.K.
        • et al.
        Large lungs and growth hormone: an increased alveolar number?.
        Eur Respir J. 1995; 8: 938-947
        • Lie J.T.
        Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients.
        Am Heart J. 1980; 100: 41-52
        • Minniti G.
        • Jaffrain-Rea M.L.
        • Moroni C.
        • et al.
        Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics.
        Clin Endocrinol (Oxf). 1998; 49: 101-106
        • Hayward R.P.
        • Emanuel R.W.
        • Nabarro J.D.
        Acromegalic heart disease: influence of treatment of the acromegaly on the heart.
        Q J Med. 1987; 62: 41-58
        • Damjanovic S.S.
        • Neskovic A.N.
        • Petakov M.S.
        • et al.
        High output heart failure in patients with newly diagnosed acromegaly.
        Am J Med. 2002; 112: 610-616
        • Fazio S.
        • Cittadini A.
        • Cuocolo A.
        • et al.
        Impaired cardiac performance is a distinct feature of uncomplicated acromegaly.
        J Clin Endocrinol Metab. 1994; 79: 441-446
        • Colao A.
        • Cuocolo A.
        • Marzullo P.
        • et al.
        Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study.
        J Clin Endocrinol Metab. 1999; 84: 1518-1523
        • Kahaly G.
        • Olshausen K.V.
        • Mohr-Kahaly S.
        • et al.
        Arrhythmia profile in acromegaly.
        Eur Heart J. 1992; 13: 51-56
        • Rodrigues E.A.
        • Caruana M.P.
        • Lahiri A.
        • et al.
        Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle.
        Br Heart J. 1989; 62: 185-194
        • Lombardi G.
        • Colao A.
        • Marzullo P.
        • et al.
        Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.
        J Endocrinol Invest. 2002; 25: 971-976
        • Herrmann B.L.
        • Bruch C.
        • Saller B.
        • et al.
        Occurrence of ventricular late potentials in patients with active acromegaly.
        Clin Endocrinol (Oxf). 2001; 55: 201-207
        • Terzolo M.
        • Matrella C.
        • Boccuzzi A.
        • et al.
        Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features.
        J Endocrinol Invest. 1999; 22: 48-54
        • Pietrobelli D.J.
        • Akopian M.
        • Olivieri A.O.
        • et al.
        Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values.
        J Hum Hypertens. 2001; 15: 601-605
        • Minniti G.
        • Moroni C.
        • Jaffrain-Rea M.L.
        • et al.
        Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring.
        Clin Endocrinol (Oxf). 1998; 48: 149-152
        • Cannavo S.
        • Almoto B.
        • Cavalli G.
        • et al.
        Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography.
        J Clin Endocrinol Metab. 2006; 91: 3766-3772
        • Jenkins P.J.
        • Sohaib S.A.
        • Akker S.
        • et al.
        The pathology of median neuropathy in acromegaly.
        Ann Intern Med. 2000; 133: 197-201
        • Zafar A.
        • Jordan D.R.
        Enlarged extraocular muscles as the presenting feature of acromegaly.
        Ophthal Plast Reconstr Surg. 2004; 20: 334-336
        • Howard G.M.
        • English F.P.
        Occurrence of glaucoma in acromegalics.
        Arch Ophthalmol. 1965; 73: 765-768
        • Barkan A.L.
        • Stred S.E.
        • Reno K.
        • et al.
        Increased growth hormone pulse frequency in acromegaly.
        J Clin Endocrinol Metab. 1989; 69: 1225-1233
        • Greenman Y.
        • Tordjman K.
        • Kisch E.
        • et al.
        Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas.
        J Clin Endocrinol Metab. 1995; 80: 1577-1583
        • Kaltsas G.A.
        • Mukherjee J.J.
        • Jenkins P.J.
        • et al.
        Menstrual irregularity in women with acromegaly.
        J Clin Endocrinol Metab. 1999; 84: 2731-2735
        • Eskildsen P.C.
        • Kruse A.
        • Kirkegaard C.
        The pituitary-thyroid axis in acromegaly.
        Horm Metab Res. 1988; 20: 755-757
        • Kasagi K.
        • Shimatsu A.
        • Miyamoto S.
        • et al.
        Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland.
        Thyroid. 1999; 9: 791-796
        • Gasperi M.
        • Martino E.
        • Manetti L.
        • et al.
        Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study.
        J Endocrinol Invest. 2002; 25: 240-245
        • Tahara S.
        • Kurotani R.
        • Ishii Y.
        • et al.
        A case of Cushing's disease caused by pituitary adenoma producing adrenocorticotropic hormone and growth hormone concomitantly: aberrant expression of transcription factors NeuroD1 and Pit-1 as a proposed mechanism.
        Mod Pathol. 2002; 15: 1102-1105
        • Mantovani G.
        • Bondioni S.
        • Lania A.G.
        • et al.
        Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors.
        J Clin Endocrinol Metab. 2004; 89: 3007-3009
        • Coculescu M.
        • Niculescu D.
        • Lichiardopol R.
        • et al.
        Insulin resistance and insulin secretion in non-diabetic acromegalic patients.
        Exp Clin Endocrinol Diabetes. 2007; 115: 308-316
        • Kasayama S.
        • Otsuki M.
        • Takagi M.
        • et al.
        Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.
        Clin Endocrinol (Oxf). 2000; 52: 549-555
        • Lund B.
        • Eskildsen P.C.
        • Norman A.W.
        • et al.
        Calcium and vitamin D metabolism in acromegaly.
        Acta Endocrinol (Copenh). 1981; 96: 444-450
        • Ezzat S.
        • Melmed S.
        • Endres D.
        • et al.
        Biochemical assessment of bone formation and resorption in acromegaly.
        J Clin Endocrinol Metab. 1993; 76: 1452-1457
        • Lesse G.P.
        • Fraser W.D.
        • Farquharson R.
        • et al.
        Gonadal status is an important determinant of bone density in acromegaly.
        Clin Endocrinol (Oxf). 1998; 48: 59-65
        • Bonadonna S.
        • Mazziotti G.
        • Nuzzo M.
        • et al.
        Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women.
        J Bone Miner Res. 2005; 20: 1837-1844
        • Jenkins P.J.
        • Mukherjee A.
        • Shalet S.M.
        Does growth hormone cause cancer?.
        Clin Endocrinol (Oxf). 2006; 64: 115-121
        • Melmed S.
        Acromegaly and cancer: not a problem?.
        J Clin Endocrinol Metab. 2001; 86: 2929-2934
        • Jenkins P.J.
        • Besser M.
        Clinical perspective: acromegaly and cancer: a problem.
        J Clin Endocrinol Metab. 2001; 86: 2935-2941
        • Renehan A.G.
        • Bhaskar P.
        • Painter J.E.
        • et al.
        The prevalence and characteristics of colorectal neoplasia in acromegaly.
        J Clin Endocrinol Metab. 2000; 85: 3417-3424
        • Jenkins P.J.
        • Frajese V.
        • Jones A.M.
        • et al.
        Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.
        J Clin Endocrinol Metab. 2000; 85: 3218-3221
        • Ezzat S.
        • Strom C.
        • Melmed S.
        Colon polyps in acromegaly.
        Ann Intern Med. 1991; 114: 754-755
        • Orme S.M.
        • McNally R.J.
        • Cartwright R.A.
        • et al.
        Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.
        J Clin Endocrinol Metab. 1998; 83: 2730-2734
        • Melmed S.
        Medical progress: acromegaly.
        N Engl J Med. 2006; 355: 2558-2573
        • Ayuk J.
        • Clayton R.N.
        • Holder G.
        • et al.
        Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
        J Clin Endocrinol Metab. 2004; 89: 1613-1617
        • Holdaway I.M.
        • Rajasoorya R.C.
        • Gamble G.D.
        Factors influencing mortality in acromegaly.
        J Clin Endocrinol Metab. 2004; 89: 667-674
        • Kauppinen-Makelin R.
        • Sane T.
        • Reunanen A.
        • et al.
        A nationwide survey of mortality in acromegaly.
        J Clin Endocrinol Metab. 2005; 90: 4081-4086
        • Sheppard M.C.
        GH and mortality in acromegaly.
        J Endocrinol Invest. 2005; 28: 75-77
        • Pokrajac A.
        • Wark G.
        • Ellis A.R.
        • et al.
        Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.
        Clin Endocrinol (Oxf). 2007; 67: 65-70
        • Bidlingmaier M.
        • Strasburger C.J.
        Growth hormone assays: current methodologies and their limitations.
        Pituitary. 2007; 10: 115-119
        • Clemmons D.R.
        IGF-I assays: current assay methodologies and their limitations.
        Pituitary. 2007; 10: 121-128
        • Melmed S.
        • Casanueva F.
        • Cavagnini F.
        • et al.
        Consensus statement: medical management of acromegaly.
        Eur J Endocrinol. 2005; 153: 737-740
        • Trainer P.J.
        • Barth J.
        • Sturgeon C.
        • et al.
        Consensus statement on the standardisation of GH assays.
        Eur J Endocrinol. 2006; 155: 1-2
        • Popii V.
        • Baumann G.
        Laboratory measurement of growth hormone.
        Clin Chim Acta. 2004; 350: 1-16
        • Freda P.U.
        • Nuruzzaman A.T.
        • Reyes C.M.
        • et al.
        Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
        J Clin Endocrinol Metab. 2004; 89: 495-500
        • Gittoes N.J.
        • Sheppard M.C.
        • Johnson A.P.
        • et al.
        Outcome of surgery for acromegaly—the experience of a dedicated pituitary surgeon.
        QJM. 1999; 92: 741-745
        • Shimon I.
        • Cohen Z.R.
        • Ram Z.
        • et al.
        Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients.
        Neurosurgery. 2001; 48 ([discussion: 1244–5]): 1239-1243
        • Kreutzer J.
        • Vance M.L.
        • Lopes M.B.
        • et al.
        Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
        J Clin Endocrinol Metab. 2001; 86: 4072-4077
        • Ahmed S.
        • Elsheikh M.
        • Stratton I.M.
        • et al.
        Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience.
        Clin Endocrinol (Oxf). 1999; 50: 561-567
        • Laws E.R.
        • Vance M.L.
        • Thapar K.
        Pituitary surgery for the management of acromegaly.
        Horm Res. 2000; 53: 71-75
        • Fahlbusch R.
        • Keller B.
        • Ganslandt O.
        • et al.
        Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging.
        Eur J Endocrinol. 2005; 153: 239-248
        • Schwartz T.H.
        • Stieg P.E.
        • Anand V.K.
        Endoscopic transsphenoidal pituitary surgery with intraoperative magnetic resonance imaging.
        Neurosurgery. 2006; 58: ONS44-ONS51
        • Jho H.D.
        Endoscopic transsphenoidal surgery.
        J Neurooncol. 2001; 54: 187-195
        • Patel Y.C.
        Somatostatin and its receptor family.
        Front Neuroendocrinol. 1999; 20: 157-198
        • Barnard L.B.
        • Grantham W.G.
        • Lamberton P.
        • et al.
        Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201–995).
        Ann Intern Med. 1986; 105: 856-861
        • Freda P.U.
        Somatostatin analogs in acromegaly.
        J Clin Endocrinol Metab. 2002; 87: 3013-3018
        • Biermasz N.R.
        • Romijn J.A.
        • Pereira A.M.
        • et al.
        Current pharmacotherapy for acromegaly: a review.
        Expert Opin Pharmacother. 2005; 6: 2393-2405
      1. Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Molecular and Cellular Endocrinology, in press.

        • Colao A.
        • Attanasio R.
        • Pivonello R.
        • et al.
        Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
        J Clin Endocrinol Metab. 2006; 91: 85-92
        • Bronstein M.
        • Musolino N.
        • Jallad R.
        • et al.
        Pharmacokinetic profile of lanreotide autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.
        Clin Endocrinol (Oxf). 2005; 63: 514-519
        • Attanasio R.
        • Baldelli R.
        • Pivonello R.
        • et al.
        Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
        J Clin Endocrinol Metab. 2003; 88: 5258-5265
        • Ayuk J.
        • Stewart S.E.
        • Stewart P.M.
        • et al.
        Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
        J Clin Endocrinol Metab. 2002; 87: 4142-4146
        • Bevan J.S.
        • Atkin S.L.
        • Atkinson A.B.
        • et al.
        Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
        J Clin Endocrinol Metab. 2002; 87: 4554-4563
        • Colao A.
        • Ferone D.
        • Marzullo P.
        • et al.
        Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
        J Clin Endocrinol Metab. 2001; 86: 2779-2786
        • Chanson P.
        • Boerlin V.
        • Ajzenberg C.
        • et al.
        Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
        Clin Endocrinol (Oxf). 2000; 53: 577-586
        • Cozzi R.
        • Dallabonzana D.
        • Attanasio R.
        • et al.
        A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
        Eur J Endocrinol. 1999; 141: 267-271
        • Turner H.E.
        • Vadivale A.
        • Keenan J.
        • et al.
        A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
        Clin Endocrinol (Oxf). 1999; 51: 275-280
        • Lancranjan I.
        • Atkinson A.B.
        Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.
        Pituitary. 1999; 1: 105-114
        • Davies P.H.
        • Stewart S.E.
        • Lancranjan L.
        • et al.
        Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
        Clin Endocrinol (Oxf). 1998; 48: 311-316
        • Flogstad A.K.
        • Halse J.
        • Bakke S.
        • et al.
        Sandostatin LAR in acromegalic patients: long-term treatment.
        J Clin Endocrinol Metab. 1997; 82: 23-28
        • Lancranjan I.
        • Bruns C.
        • Grass P.
        • et al.
        Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients.
        Metabolism. 1996; 45: 67-71
        • Amato G.
        • Mazziotti G.
        • Rotondi M.
        • et al.
        Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
        Clin Endocrinol (Oxf). 2002; 56: 65-71
        • Verhelst J.A.
        • Pedroncelli A.M.
        • Abs R.
        • et al.
        Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
        Eur J Endocrinol. 2000; 143: 577-584
        • Baldelli R.
        • Colao A.
        • Razzore P.
        • et al.
        Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
        J Clin Endocrinol Metab. 2000; 85: 4099-4103
        • Caron P.
        • Morange-Ramos I.
        • Cogne M.
        • et al.
        Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
        J Clin Endocrinol Metab. 1997; 82: 18-22
        • al-Maskari M.
        • Gebbie J.
        • Kendall-Taylor P.
        The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
        Clin Endocrinol (Oxf). 1996; 45: 415-421
        • Ambrosio M.R.
        • Franceschetti P.
        • Bondanelli M.
        • et al.
        Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
        Metabolism. 2002; 51: 387-393
        • Caron P.
        • Cogne M.
        • Raingeard I.
        • et al.
        Effectiveness and tolerability of 3-year lanreotide autogel treatment in patients with acromegaly.
        Clin Endocrinol (Oxf). 2006; 64: 209-214
        • Lucas T.
        • Astorga R.
        Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
        Clin Endocrinol (Oxf). 2006; 65: 320-326
        • Gutt B.
        • Bidlingmaier M.
        • Kretschmar K.
        • et al.
        Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
        Exp Clin Endocrinol Diabetes. 2005; 113: 139-144
        • Caron P.
        • Beckers A.
        • Cullen D.R.
        • et al.
        Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
        J Clin Endocrinol Metab. 2002; 87: 99-104
        • Ronchi C.L.
        • Varca V.
        • Beck-Peccoz P.
        • et al.
        Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors.
        J Clin Endocrinol Metab. 2006; 91: 121-128
        • Freda P.U.
        • Katznelson L.
        • van der Lely A.J.
        • et al.
        Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
        J Clin Endocrinol Metab. 2005; 90: 4465-4473
        • Ben-Shlomo A.
        • Melmed S.
        Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly.
        J Clin Endocrinol Metab. 2003; 88: 963-968
        • Colao A.
        • Spinelli L.
        • Cuocolo A.
        • et al.
        Cardiovascular consequences of early-onset growth hormone excess.
        J Clin Endocrinol Metab. 2002; 87: 3097-3104
        • Baldelli R.
        • Ferretti E.
        • Jaffrain-Rea M.L.
        • et al.
        Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients.
        J Clin Endocrinol Metab. 1999; 84: 527-532
        • Hradec J.
        • Kral J.
        • Janota T.
        • et al.
        Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog).
        Am J Cardiol. 1999; 83: 1506-1509
        • Al-Khatib S.M.
        • LaPointe N.M.
        • Kramer J.M.
        • et al.
        What clinicians should know about the QT interval.
        JAMA. 2003; 289: 2120-2127
        • Ronchi C.
        • Epaminonda P.
        • Cappiello V.
        • et al.
        Effects of two different somatostatin analogs on glucose tolerance in acromegaly.
        J Endocrinol Invest. 2002; 25: 502-507
        • Newman C.B.
        • Melmed S.
        • Snyder P.J.
        • et al.
        Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients—a clinical research center study.
        J Clin Endocrinol Metab. 1995; 80: 2768-2775
      2. Rx List, The Internet Drug Index. Sandostatin LAR. Available at: www.rxlist.com.

        • Lucas T.
        • Astorga R.
        • Catala M.
        Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
        Clin Endocrinol (Oxf). 2003; 58: 471-481
        • Giusti M.
        • Gussoni G.
        • Cuttica C.M.
        • et al.
        Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian multicenter slow release lanreotide Study Group.
        J Clin Endocrinol Metab. 1996; 81: 2089-2097
        • Marek J.
        • Hana V.
        • Krsek M.
        • et al.
        Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide.
        Eur J Endocrinol. 1994; 131: 20-26
        • Morange I.
        • De Boisvilliers F.
        • Chanson P.
        • et al.
        Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
        J Clin Endocrinol Metab. 1994; 79: 145-151
        • Bruttomesso D.
        • Fongher C.
        • Silvestri B.
        • et al.
        Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients.
        Diabetes Res Clin Pract. 2001; 51: 97-105
        • Schade R.
        • Andersohn F.
        • Suissa S.
        • et al.
        Dopamine agonists and the risk of cardiac-valve regurgitation.
        N Engl J Med. 2007; 356: 29-38
        • Chen W.Y.
        • White M.E.
        • Wagner T.E.
        • et al.
        Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice.
        Endocrinology. 1991; 129: 1402-1408
        • Chen W.Y.
        • Wight D.C.
        • Wagner T.E.
        • et al.
        Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice.
        Proc Natl Acad Sci USA. 1990; 87: 5061-5065
        • Fuh G.
        • Cunningham B.C.
        • Fukunaga R.
        • et al.
        Rational design of potent antagonists to the human growth hormone receptor.
        Science. 1992; 256: 1677-1680
        • Muller A.F.
        • Kopchick J.J.
        • Flyvbjerg A.
        • et al.
        Clinical review 166: growth hormone receptor antagonists.
        J Clin Endocrinol Metab. 2004; 89: 1503-1511
        • Kopchick J.J.
        • Parkinson C.
        • Stevens E.C.
        • et al.
        Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
        Endocr Rev. 2002; 23: 623-646
        • Trainer P.J.
        • Drake W.M.
        • Katznelson L.
        • et al.
        Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
        N Engl J Med. 2000; 342: 1171-1177
        • van der Lely A.J.
        • Hutson R.K.
        • Trainer P.J.
        • et al.
        Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
        Lancet. 2001; 358: 1754-1759
        • Barkan A.L.
        • Burman P.
        • Clemmons D.R.
        • et al.
        Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.
        J Clin Endocrinol Metab. 2005; 90: 5684-5691
        • Colao A.
        • Pivonello R.
        • Auriemma R.S.
        • et al.
        Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
        Eur J Endocrinol. 2006; 154: 467-477
        • Lindberg-Larsen R.
        • Moller N.
        • Schmitz O.
        • et al.
        The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
        J Clin Endocrinol Metab. 2007; 92: 1724-1728
        • De Marinis L.
        • Bianchi A.
        • Fusco A.
        • et al.
        Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
        Pituitary. 2007; 10: 227-232
        • Frohman L.A.
        • Bonert V.
        Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
        Pituitary. 2007; 10: 283-289
        • Feenstra J.
        • van Aken M.O.
        • de Herder W.W.
        • et al.
        Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.
        Eur J Endocrinol. 2006; 154: 805-806
        • Biering H.
        • Saller B.
        • Bauditz J.
        • et al.
        Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
        Eur J Endocrinol. 2006; 154: 213-220
        • Jorgensen J.O.
        • Feldt-Rasmussen U.
        • Frystyk J.
        • et al.
        Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
        J Clin Endocrinol Metab. 2005; 90: 5627-5631
        • Feenstra J.
        • de Herder W.W.
        • ten Have S.M.
        • et al.
        Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
        Lancet. 2005; 365: 1644-1646
        • Maffei P.
        • Martini C.
        • Pagano C.
        • et al.
        Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant.
        Ann Intern Med. 2006; 145: 310-312
        • Colao A.
        • Ferone D.
        • Marzullo P.
        • et al.
        Effect of different dopaminergic agents in the treatment of acromegaly.
        J Clin Endocrinol Metab. 1997; 82: 518-523
        • Abs R.
        • Verhelst J.
        • Maiter D.
        • et al.
        Cabergoline in the treatment of acromegaly: a study in 64 patients.
        J Clin Endocrinol Metab. 1998; 83: 374-378
        • Muratori M.
        • Arosio M.
        • Gambino G.
        • et al.
        Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
        J Endocrinol Invest. 1997; 20: 537-546
        • Zanettini R.
        • Antonini A.
        • Gatto G.
        • et al.
        Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
        N Engl J Med. 2007; 356: 39-46
        • Jenkins P.J.
        • Bates P.
        • Carson M.N.
        • et al.
        Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.
        J Clin Endocrinol Metab. 2006; 91: 1239-1245
        • Eastman R.C.
        • Gorden P.
        • Glatstein E.
        • et al.
        Radiation therapy of acromegaly.
        Endocrinol Metab Clin North Am. 1992; 21: 693-712
        • Jezkova J.
        • Marek J.
        • Hana V.
        • et al.
        Gamma knife radiosurgery for acromegaly—long-term experience.
        Clin Endocrinol (Oxf). 2006; 64: 588-595
        • Jallad R.S.
        • Musolino N.R.
        • Kodaira S.
        • et al.
        Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?.
        Clin Endocrinol (Oxf). 2007; 67: 310-315